Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00801632 · ClinicalTrials.gov registry record · Phase 2
Combined Kidney and Bone Marrow Transplantation to Prevent Kidney Transplant Rejection
A Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT00801632 is a Phase 2 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 5 participants.
The verdict
NCT00801632, a Phase 2 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
In small initial studies, combined kidney and bone marrow transplants from the same donor have permitted some individuals to stop taking anti-rejection medicines without rejecting their transplant. This clinical trial will study this method in a greater number of people to determine if it is indeed effective and safe.
Interventions
- DRUG cyclophosphamide
- BIOLOGICAL rituximab
- PROCEDURE Kidney Transplantation
- PROCEDURE Bone marrow transplantation
- BIOLOGICAL MEDI-507
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2008-12 |
| Est. Completion | 2014-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00801632
The ClinicalTrials.gov registry entry for NCT00801632 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00801632 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00801632 about?
NCT00801632 is a clinical study titled "Combined Kidney and Bone Marrow Transplantation to Prevent Kidney Transplant Rejection". In small initial studies, combined kidney and bone marrow transplants from the same donor have permitted some individuals to stop taking anti-rejection medicines without rejecting their transplant. This clinical trial will study this method in a greater number of people to determine if it is indeed ...
What is the current status of trial NCT00801632?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2008-12. Estimated completion is 2014-11.
What interventions are being tested in trial NCT00801632?
The interventions under investigation include: cyclophosphamide (DRUG), rituximab (BIOLOGICAL), Kidney Transplantation (PROCEDURE), Bone marrow transplantation (PROCEDURE), MEDI-507 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00801632?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.